Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Langenbeck's Archives of Surgery
Published in: Langenbeck's Archives of Surgery 4/2006

01-08-2006 | Original Article

Randomized trial of the efficacy of adjuvant chemotherapy for colon cancer with combination therapy incorporating the oral pyrimidine 1-hexylcarbamoyl-5-fluorouracil

Authors: Masahiko Watanabe, Susumu Kodaira, Takashi Takahashi, Takeshi Tominaga, Keiichi Hojo, Tomoyuki Kato, Kazufumi Kunitomo, Hiroharu Isomoto, Yasuo Ohashi, Masayuki Yasutomi

Published in: Langenbeck's Archives of Surgery | Issue 4/2006

Login to get access

Abstract

Background and aims

The purpose of the present trial was to clarify the efficacy of postoperative adjuvant chemotherapy including an oral fluoropyrimidine anticancer drug, the 1-hexylcarbamoyl-5-fluorouracil (HCFU), for the treatment of colon cancer.

Method

Patients with clinical stage Dukes’ B and C colon cancer, who had been treated surgically, were assigned to a chemotherapy group treated with mitomycin C, 5-fluorouracil (5-FU), and HCFU and to a control group that received no postoperative adjuvant chemotherapy.

Results

Of the 1,001 patients registered for the study, 17 (1.7%) were ineligible. The incidence of toxicity was significantly higher in the chemotherapy group than in the control group. However, there were few severe side effects and no deaths related to the treatment. Overall survival showed no significant difference between the groups. The disease-free survival or the recurrence-free intervals was significantly higher in the chemotherapy group than in the control group. The incidence of hepatic recurrence was significantly (P=0.003) lower in the chemotherapy group than in the control group.

Conclusion

The results of this study demonstrated the efficacy of adjuvant chemotherapy for colon cancer, i.e., combined chemotherapy that included the 5-FU oral anticancer drug HCFU.
Literature
1.
2.
Wils J, O’Dwyer P, Labianca R (2001) Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. Ann Oncol 12:13–22PubMedCrossRef
3.
Ragnhammar P, Hafstrom L, Nygren P (2001) A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 40:282–308PubMedCrossRef
4.
Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, McCormack GW, Gerstner JB, Krook JE, Malliard J (1989) Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 7:1447–1456PubMed
5.
Wolmark N, Rockette H, Mamounas E, Jone J, Wieand S, Wickerham DL, Bear HD, Atkins JN, Dimitrov NV, Glass AG, Fisher ER, Fisher B (1999) Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from national surgical adjuvant breast and bowel project C-04. J Clin Oncol 17:3553–3559PubMed
6.
Sakamoto J, Hamada C, Kodaira S, Nakazato H, Ohashi Y (1999) Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patients data meta-analysis of randomized trials. Jpn J Clin Oncol 29:78–86PubMedCrossRef
7.
Miyauchi M, Yamamoto N, Matsumoto M, Shishikura T, Hyakutake K (2000) Comparative clinical study on 5-FU concentrations for oral HCFU and i.v. 5-FU. Gan To Kagaku Ryoho 27:1011–1014PubMed
8.
Koyama Y (1981) 1-Hexylcarbamoyl-5-fluorouracil (HCFU)—a masked 5-fluorinated pyrimidine. Cancer Treat Rev 8:147–156PubMedCrossRef
9.
Sugimachi K, Maehara Y, Ogawa M, Kakegawa T, Tomita M, Akiyoshi T (1996) Postoperative chemotherapy for colorectal cancer by combining 5-fluorouracil infusion and 1-hexylcarbamoyl-5-fluorouracil administration after curative resection. Cancer 77:36–43PubMedCrossRef
10.
Ito K, Yamaguchi A, Miura K, Kato T, Koike A, Takagi H (1996) Prospective adjuvant therapy with mitomycin C and carmofur (HCFU) for colorectal cancer, 10-year follow-up: Tokai HCFU Study Group, the first study for colorectal cancer. J Surg Oncol 62:4–9PubMedCrossRef
11.
Ito K, Yamaguchi A, Miura K, Kato T, Baba S, Matsumoto S, Ishii M, Takagi H (1996) Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: five-year follow-up. Tokai HCFU Study Group—third study on colorectal cancer. J Surg Oncol 63:107–111PubMedCrossRef
12.
Sakamoto J, Kodaira S, Hamada C, Ito K, Maehara Y, Takagi H, Sugimachi K, Nakazato H, Ohashi Y, Meta-analysis Group of the Japanese Society of Strategies for Cancer Research and Therapy (2001) An individual patient data meta-analysis of long supported adjuvant chemotherapy with oral carmofur in patients with curatively resected colorectal cancer. Oncol Rep 8:697–703PubMed
13.
Yasutomi M, Takahashi T, Kodaira S, Hojo K, Kato T, Ogawa M, Ichihashi H, Tominaga T, Tamada R, Kunii Y, Kikuchi K (1997) Prospective controlled study on the usefulness of Carmofur as a postoperative adjuvant chemotherapy for colorectal cancer. Gan To Kagaku Ryoho 24:1953–1960PubMed
14.
Watanabe M, Nishida O, Kunii Y, Koraira S, Takahashi T, Tominaga T, Hojo K, Kato T, Niimoto M, Kunitomo K, Isomoto H, Ohashi Y, Yasutomi M (2004) Randomized controlled trial on the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-fluorouracil and uracil/tegafur. Int J Clin Oncol 9:98–106PubMedCrossRef
15.
Japanese Society for Cancer of the Colon and Rectum (1985) Japanese classification of colorectal carcinoma, 4th edn. Kanehara Ltd., Tokyo
16.
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef
17.
Ito K, Yamaguchi A, Miura K, Kato K, Baba S, Matsumoto S, Ishii M, Takagi H (2000) Effect of oral adjuvant therapy with Carmofur (HCFU) for distant metastasis of colorectal cancer. Int J Clin Oncol 5:29–35CrossRef
18.
International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators (1995) Efficacy of adjuvant fluorouracil and folinic acid in colorectal cancer. Lancet 345:939–944CrossRef
19.
Zaniboni A (1997) Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival. J Clin Oncol 15:2432–2441PubMed
20.
Meropol NJ, Sonnichsen DS, Birkhofer MJ (1997) Oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. Oncology 11:22–25PubMed
21.
Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, Vincent MD, Lembersky BC, Thompson S, Maniero A, Benner SE (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3605–3616PubMedCrossRef
22.
Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, Skovsgaard T, Munier S, Martin C (2002) Randomised comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3617–3627PubMedCrossRef
23.
Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282–2292PubMed
24.
Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P, Xeloda Colorectal Cancer Study Group (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097–4106PubMed
25.
Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C (1998) Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407–1412PubMedCrossRef
26.
Douillard J, Cunningham D, Roth A, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 355:1041–1047PubMedCrossRef
27.
Van Cutsem E, Pozzo C, Starkhammar H, Dirix L, Terzoli E, Cognetti F, Humblet Y, Garufi C, Filez L, Gruia G, Cote C, Barone C (1998) A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colon cancer. Ann Oncol 9:1199–1204PubMedCrossRef
28.
Levi F, Zidani R, Misset JL (1997) Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chemotherapy. Lancet 350:681–686PubMedCrossRef
29.
De Gramont A, Banzi M, Navarro M, Tabernero J, Hickish T, Bridgewater J, Rivera F, Figer A, Fountzilas G, Andre T (2003) Oxaliplatin/5-FU/LV in adjuvant colon cancer: results of the international randomized mosaic trial. Proc Am Soc Clin Oncol 22:253(Abstr 1015)
Metadata
Title
Randomized trial of the efficacy of adjuvant chemotherapy for colon cancer with combination therapy incorporating the oral pyrimidine 1-hexylcarbamoyl-5-fluorouracil
Authors
Masahiko Watanabe
Susumu Kodaira
Takashi Takahashi
Takeshi Tominaga
Keiichi Hojo
Tomoyuki Kato
Kazufumi Kunitomo
Hiroharu Isomoto
Yasuo Ohashi
Masayuki Yasutomi
Publication date
01-08-2006
Publisher
Springer-Verlag
Published in
Langenbeck's Archives of Surgery / Issue 4/2006
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-006-0044-6

Other articles of this Issue 4/2006

Langenbeck's Archives of Surgery 4/2006 Go to the issue

Original Article

The treatment of intrahepatic calculosis by applying helix hydro-jet lithotripsy under video choledochoscope: a report of 30 cases

Current Concepts in Clinical Surgery

Surgical treatment of superficial esophageal cancer

Letter to the Editor

Reply to the letter by C. Chauveau et al. on our publication “A comparative analysis of phenotype expression in human osteoblasts from heterotopic ossification and normal bone”

Editorial

Randomized controlled clinical trials—support but not substitute of decision-making in surgery

Original Article

Assessment of risk-independent follow-up to detect asymptomatic recurrence after curative resection of colorectal cancer

Original Article

Predictive factors of liver injury in blunt multiple trauma